Our comprehensive guide hospitals information helps you quickly locate a hospital anywhere in the world. Our database contains in excess of 16,000 hospitals, making it one of the best places to find information on the hospital you are searching for. To assist you with locating a hospital, you can refine your search by selecting the country in which the hospital is located and choose to search by either hospital name, city/town or state/county.

 Home>> Increlex (mecasermin)

Increlex (mecasermin)

General Information

Increlex (mecasermin) contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized statural growth. Patients with severe primary IGF-1 deficiency (Primary IGFD) fail to produce adequate levels of IGF-1, due to disruption of the growth hormone (GH) pathway used to promote IGF-1 release (possible GH pathway disruptions include mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects).

Increlex is specifically indicated for the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.

Increlex is supplied as a sterile, aqueous, clear and colorless solution intended for subcutaneous injection. Dosing should be titrated on a per-patient basis: the recommended initial dose is 40-80 mcg/kg twice daily. The dose can be increased in 40 mcg/kg/dose increments if well tolerated for one week, to a maximum dose of 120 mcg/kg twice daily.


Additional Information

For additional information regarding Increlex or growth failure due to Primary IGFD, please visit the Increlex web page.


Clinical Results

FDA Approval
Approval of Increlex was based on five clinical trials of the drug: four were open-label studies, and one was double-blind and placebo-controlled. The studies enrolled a total of 71 children suffering from extreme short stature; all children exhibited symptoms of Primary IGFD, including slow growth rates, low IGF-1 serum concentrations, and normal growth hormone secretion. Pooled results from these studies indicated that administration of Increlex increased height velocity significantly compared to baseline for years 1 through 6:


  • Year 1: + 5.2 cm/year, n=58, p<0.0001
  • Year 2: + 2.9 cm/year, n=48, p<0.0001
  • Year 3: + 2.3 cm/year, n=38, p<0.0001
  • Year 4: + 1.5 cm/year, n=23, p=0.0045
  • Year 5: + 1.5 cm/year, n=21, p=0.0015
  • Year 6: + 1.5 cm/year, n=20, p=0.0009

Increlex was also shown to increase bone maturation rate in 49 subjects, with bone age increasing 8.1% faster than chronological age (+5.3 years vs. +4.9 years).


Mechanism of Action

Increlex supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.


Literature References

Side effects

Adverse events associated with the use of Symlin may include, but are not limited to, the following:

  • Bruising
  • Lipohypertrophy
  • Otitis Media
  • Snoring
  • Headache
  • Dizziness
  • Convulsions
  • Vomiting
  • Ear pain
  • Hypoacusis
  • Cardiac Murmur
  • Arthralgia

Hypoglycemia, thought to be related to the drug's insulin-like activities, occurred in a significant portion of patients (42%) during their course of therapy. While most cases were mild or moderate, 5 subjects had severe hypoglycemia on one or more occasions, and 4 subjects experienced hypoglycemic seizures/loss of consciousness. Risk of hypoglycemia was generally mediated when a meal or snack was consumed 20 minutes prior to Increlex administration.

Also, as the drug is a pharmaceutical protein, anti-Increlex/anti-IGF-1 antibody formation can occur. 14 of 23 subjects treated for 2 years with the drug experienced some degree of anti-IGF-1 antibody formation, though no clinical consequences (allergic reaction or loss of efficacy) were observed.


Treatment

Growth Failure

Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Ranitidine Capsules Natazia (estradiol valerate + dienogest) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alinia (nitazoxanide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Botox Cosmetic (botulinum toxin type A) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Anthim (obiltoxaximab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Byvalson (nebivolol and valsartan) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alimta (pemetrexed for injection) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Quixin (levofloxacin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rapivab (peramivir injection) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alvesco (ciclesonide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Advair (fluticasone propionate and salmeterol) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Onglyza (saxagliptin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pegasys (peginterferon alfa-2a) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cambia (diclofenac potassium for oral solution) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rayos (prednisone) delayed-release tablets Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Ranitidine Tablets Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Campath Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Remicade (infliximab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prestalia (perindopril arginine and amlodipine besylate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rituxan Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Infasurf Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Aldara (imiquimod) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Renova (tretinoin emollient cream) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Auryxia (Ferric citrate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pomalyst (pomalidomide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Promacta (eltrombopag) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Lyrica (pregabalin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pentoxifylline Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Ultracet (acetaminophen and tramadol HCl) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rocephin Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Qnasl (beclomethasone dipropionate) nasal aerosol Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print AneuVysion Assay Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Letairis (ambrisentan) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Anzemet Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Axona (caprylidene) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Propecia Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Potiga (ezogabine) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Zenapax